ER is an oncogenic transcription factor in breast and endometrial cancer that is activated by binding to estrogens, such as endogenous 17β-estradiol (E2) (Rodriguez et al. 2019; Shen et al. 2016; Zwart et al. 2011). The gene discussed is ESR1; the disease is endometrial cancer.